Cyteir Therapeutics
Cyteir was a clinical-stage oncology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir had CYT-0851 in development in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
11 to 50
headcount range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
1
tools in use
Monthly traffic
132
organic / mo
Sign up free to see all 5 verified contacts at Cyteir Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- RP
Rachel Proffitt
Lead Clinical Logistics Coordinator · Other
EmailPhone - RB
Racquel Bracken
Board Member · General Business & Management
EmailPhone - TO
Tom Oshea
Senior Vice President, Clinical Pharmacology & Preclinical Development · Other
EmailPhone
Showing 3 of 5 verified contacts
Top roles at Cyteir Therapeutics
5 distinct titles indexed · top 5 shown.
- 1board member
- 1board member, chairman
- 1head of biomrkers
- 1lead clinical logistics coordinator
- 1senior vice president, clinical pharmacology & preclinical development
Sign up to unlock all 5 contacts at Cyteir Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Cyteir Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.